Searches , social queries for DONANEMAB
Search references for DONANEMAB. Phrases containing DONANEMAB
See searches and references containing DONANEMAB!
Search references for DONANEMAB. Phrases containing DONANEMAB
See searches and references containing DONANEMAB!DONANEMAB
Monoclonal antibody against amyloid beta
Donanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. Donanemab was developed by Eli Lilly
Donanemab
Drug class
effect in the treatment of Alzheimer's disease. As of 2025, lecanemab and donanemab are the only drugs to have been approved by the European Medicines Agency
Anti-amyloid_antibodies
Antibodies from clones of the same blood cell
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Monoclonal_antibody
Investigational gamma-secretase modulator
Same Kindred, to Evaluate the Efficacy and Safety of Donanemab, RG6289, or the Combination of Donanemab and RG6289, in the Treatment of Autosomal-Dominant
Nivegacetor
Progressive neurodegenerative disease
Two monoclonal antibodies have been approved to target amyloid beta – donanemab and lecanemab – but as of 2025, their role in treatment is uncertain because
Alzheimer's_disease
Cognitive decline
made possible the development of anti-amyloid immunotherapies, such as donanemab, and lecanemab, for use in mild NCI due to Alzheimer's or in mild Alzheimer's
Dementia
Pharmaceutical drug
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Evolocumab
American pharmaceutical company
obesity under the brand name Zepbound. In 2024, the FDA and the UK approved Donanemab, sold under the brand name Kisunla, a monoclonal antibody used for the
Eli_Lilly_and_Company
Monoclonal antibody against amyloid beta
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Lecanemab
Experimental monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Prasinezumab
Medication
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Bevacizumab
Monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Rinucumab
Monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Bedinvetmab
Activation or suppression of the immune system to treat disease
occurs later. As of 2026, two anti-Aβ antibodies – lecanemab (Leqembi) and donanemab (Kisunla) – have been approved by the U.S. FDA to treat mild cognitive
Immunotherapy
Chemical compound
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Bimagrumab
Medication
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Marstacimab
Veterinary medication
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Relfovetmab
Monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Emicizumab
Human monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Denosumab
Pharmaceutical biological monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Fremanezumab
Pharmaceutical drug classification
extract N06DX01 Memantine N06DX03 Aducanumab N06DX04 Lecanemab N06DX05 Donanemab N06DX06 Blarcamesine N06DX07 Hydromethylthionine N06DX08 Viquidil N06DX09
ATC_code_N06
Chemical compound
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Erenumab
Pharmaceutical drug
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Alirocumab
Medication
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Concizumab
Antibodies from non-human species made nearly identical to human ones
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Humanized_antibody
Chemical compound
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Caplacizumab
Monoclonal antibody against amyloid beta
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Aducanumab
Pharmaceutical drug
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Romosozumab
Pharmaceutical compound
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Abciximab
Anti-tau monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Semorinemab
Health and Care Excellence (NICE) announces that the Alzheimer's drug Donanemab will not be made available on the NHS in England because of its cost and
2024_in_the_United_Kingdom
sclerosis Domagrozumab mab humanized GDF-8 Duchenne muscular dystrophy Donanemab Kisunla mab humanized Amyloid beta Y Alzheimer's disease Dorlimomab aritox
List of therapeutic monoclonal antibodies
List_of_therapeutic_monoclonal_antibodies
Chemical compound
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Blosozumab
Monoclonal antibody medication
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Solanezumab
Drugs that inhibit α-synuclein
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Anti-α-synuclein_drug
Monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Eptinezumab
Monoclonal antibody designed to treat X-linked hypophosphatemia
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Burosumab
Monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Galcanezumab
hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH) Donanemab Treatment of Alzheimer’s disease Dupilumab Regeneron As an add-on maintenance
List of drugs granted breakthrough therapy designation
List_of_drugs_granted_breakthrough_therapy_designation
Medication
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Idarucizumab
Veterinary medication
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Izenivetmab
Monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Trevogrumab
Monoclonal antibody protein
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Gantenerumab
Monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Abelacimab
domitroban (INN) domoprednate (INN) domoxin (INN) domperidone (INN) donanemab-azbt donanemab (INN) donepezil (INN) donetidine (INN) donidalorsen (USAN, INN)
List_of_drugs:_Do
Monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Refanezumab
Dementia research charity
Alzheimer's Research UK suggested that clinical trials for lecanemab and donanemab would only find 575,000 people living in the UK eligible for treatment
Alzheimer's_Research_UK
and Care Excellence (NICE) decides not to make two Alzheimer's drugs, donanemab and lecanemab, available for use by the NHS after deeming them to be too
2025_in_the_United_Kingdom
Pharmaceutical drug
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Ranibizumab
Chemical compound
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Bapineuzumab
Monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Ozanezumab
Form of immunotherapy
Bapineuzumab, Solanezumab, Gautenerumab, Crenezumab, Aducanemab, Lecanemab and Donanemab. Bapineuzumab, a humanized anti-Aβ mAb, is directed against the N-terminus
Monoclonal_antibody_therapy
Chemical compound
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Bococizumab
Drug Administration approval — aducanumab (2021), lecanemab (2023), and donanemab (2024) — each reducing brain amyloid but producing modest cognitive benefits
George_Perry_(neuroscientist)
low-income-affected people. 3 May Drug company Eli Lilly reports that donanemab can slow the pace of Alzheimer's disease by 35%, following a Phase 3 study
2023_in_science
Antibody tested against Alzheimer's
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Crenezumab
Monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Stamulumab
Monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Vanucizumab
Medication for macular degeneration
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Faricimab
Pharmaceutical drug
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Brolucizumab
Medication
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Bentracimab
Monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Inclacumab
Monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Enoticumab
Monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Evinacumab
Pharmaceutical drug
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Ramucirumab
Monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Opicinumab
Monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Volociximab
Monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Icrucumab
Experimental monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Cinpanemab
Monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Fasinumab
Monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Ralpancizumab
Pharmaceutical compound
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Devextinetug
Monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Demcizumab
Pharmaceutical compound
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Amlenetug
Monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Etaracizumab
Chemical compound
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Tanezumab
Pharmaceutical compound
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Indium_(111In)_imciromab
Chemical compound
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Fulranumab
Monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Nesvacumab
Chemical compound
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Ascrinvacumab
Monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Orticumab
Monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Tadocizumab
Pharmaceutical drug
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Alacizumab_pegol
Monoclonal antibody
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Ponezumab
Pharmaceutical compound
Tadocizumab Vanucizumab Neurologic Human Anti-amyloid drugs Aducanumab‡ Donanemab Gantenerumab† Lecanemab Erenumab Fasinumab† Fulranumab Opicinumab Humanized
Indium_(111In)_biciromab
travel, tourism, insurance
DONANEMAB
DONANEMAB
DONANEMAB
DONANEMAB
DONANEMAB
DONANEMAB
DONANEMAB
DONANEMAB
DONANEMAB
travel, tourism, insurance